Cerebrospinal Fluid (Vascular Endothelial Growth Factor) and Serologic (Recoverin) Tumor Markers for Malignant Glioma

Sampath, Prakash; Weaver, Charles E.; Sungarian, Arno; Cortez, Selina; Alderson, Lloyd M.; Stopa, Edward G.

doi:10.1177/107327480401100305

Cited by 59 publications

(43 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Methods with more sensibility and specificity than the cellular morphology are necessary to correctly identify malignant cells in the CSF 23,24 . Although CSF cytology is useful, malignant cells are not detected in as many as one third of patients who have compelling clinical or radiographic evidence of neoplastic meningitis.…”

Section: Discussionmentioning

confidence: 99%

Quantification of cerebrospinal fluid ferritin as a biomarker for CNS malignant infiltration

Almeida

Cunha

Yamada

et al. 2008

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

-Several markers have been studied for their ability to make the CNS infiltration diagnosis earlier and more precise; previous studies showed that CSF ferritin concentrations were higher in patients with malignant invasion of CNS. The objective was to determine the importance of CSF ferritin as a biomarker for the diagnosis of CNS neoplasic infiltration. This study is based on 93 CSF samples, divided into five groups: malignant cells present (n13); malignant cells not present (n26); inflammatory neurological diseases (n16); neurocysticercosis (n20); acute bacterial meningitis (n18). CSF ferritin values were determined by micro particle enzyme immunoassay. CSF ferritin level (mean±SD) in the group with neoplasic cells in the CSF was 42.8±49.7 ng /mL, higher than in the other groups (p<0.0001). We conclude that CSF ferritin with the cut off 20 ng/mL could be an adjuvant biomarker to the diagnosis of CNS malignant infiltration.Key WorDS: cerebrospinal fluid, ferritin, central nervous system, malignant cells, CNS neoplasm, CNS tumors, bacterial meningitis. Quantificação de ferritina no líquido cefalorraquidiano como biomarcador para o diagnóstico de infiltração maligna no sncResumo -Diversos marcadores foram estudados com a finalidade de avaliar sua capacidade de diagnosticar a infiltração neoplásica no SNC precocemente e de forma mais precisa. estudos anteriores mostraram que as concentrações de ferritina no LCr eram mais elevadas nos pacientes com infiltração neoplásica no SNC. o objetivo foi determinar a importância da ferritina no LCr como biomarcador para o diagnóstico de infiltração neoplásica no SNC. este estudo é baseado em 93 amostras do LCr, divididas em cinco grupos: células malignas presentes (n13); células malignas ausentes (n26); doenças neurologicas inflamatórias (n16); neurocisticercose (n20); meningites bacterianas agudas (n18). os valores de ferritina no LCr foram determinados por eLISA de microparticulas. o nível de ferritina no LCr (média±desvio padrão) no grupo com células neoplásicas no LCr foi 42,8±49,7 ng/mL, mais elevado do que nos outros grupos (p<0.0001). Concluímos que a ferritina no LCr com cut off de 20 ng/mL pode ser um biomarcador para o diagnóstico de infiltração maligna no SNC.PALAvrAS-ChAve: líquido cefalorraquidiano, sistema nervoso central, células malignas, neoplasias do SNC, tumores do SNC, meningites bacterianas.

show abstract

Section: Discussionmentioning

confidence: 99%

Quantification of cerebrospinal fluid ferritin as a biomarker for CNS malignant infiltration

Almeida

Cunha

Yamada

et al. 2008

Arq. Neuro-Psiquiatr.

View full text Add to dashboard Cite

show abstract

“…The VEGF release can be induced in an epigenetic way by a series of factors such as hypoxia (mediated by the hypoxia induced factor), acid pH, infl ammatory cytokines (IL-6) and growth factors (bFGF, basic fi broblast growth factor) or it can also be directly released by the tumor cell. Sampath et al (2004) studied the presence of VEGF in the CSF of patients with high-grade gliomas and nonastrocytic tumors and found highly heterogeneous amounts among cases with the same histological grade (between 0 -17.08 ng VEGF/mg of total protein in glioblastoma). The samples obtained by LP showed less VEGF (0.00 -0.08 ng VEGF/mg of total protein) than the samples from the ventricular system obtained in patients with external ventricular drains at the time of surgery (0.41-17.08 ng VEGF/mg of total protein).…”

Section: Discussionmentioning

confidence: 99%

Angiogenic potential of the cerebrospinal fluid (CSF) of patients with high-grade gliomas measured with the chick embryo chorioallantoic membrane assay (CAM)

et al. 2012

View full text Add to dashboard Cite

ABSTRACT:High-grade gliomas are highly vascularized tumors. Neo-angiogenesis plays a key role in tumor growth and resistance to therapy. A cerebrospinal fl uid (CSF) sample could be a useful way to obtain pro-angiogenic predictive or prognostic markers at diff erent stages of the disease. As a fi rst step we looked for pro-angiogenic activity in the CSF of patients with high-grade gliomas. We performed the chicken embryo chorio-allantoic membrane (CAM) assay to study the angiogenic potential of the cerebrospinal fl uid (CSF), obtained either by lumbar puncture (LP) or craniotomy from six patients with high-grade brain tumors (three glioblastoma (WHO grade IV), one anaplastic oligodendroglioma (WHO grade III), two anaplastic ganglioglioma (WHO grade III)), and four healthy controls. Signifi cantly increased neo-angiogenesis was observed on the surface of the growing CAM in the 6 patients with high-grade gliomas compared to controls (3.69 ± 1.23 versus 2.16 ± 0.97 capillaries per area (mean ± SD), p<0.005). There was no statistical diff erence related to the hystological grade of the tumor (WHO grade III or IV), previous treatment (radio-chemotherapy plus temozolomide, temozolomide alone or no treatment), or the site of CSF sample (surgery or lumbar puncture). Our results suggest a pro-angiogenic potential in the CSF of patients with high-grade gliomas.

show abstract

“…The levels of VEGF were significantly higher in high-grade astrocytomas than in nonastrocytic tumors indicating that detection of VEGF in CSF could be a potential marker for differentiating astrocytic from nonastrocytic tumors. [48] Another group applied mass spectrometry based technology to identify possible CSF peptide markers of GBM. [49] Out of 2,000 detected CSF peptides four peptides which significantly distinguished GBM from controls were identified.…”

Section: Proteomic Analysis Of Csfmentioning

confidence: 99%

Targeting cerebrospinal fluid for discovery of brain cancer biomarkers

Shalaby¹,

Achini²,

Grotzer³

2016

JCMT

View full text Add to dashboard Cite

Central nervous system (CNS) cancer is a devastating illness with unmet therapeutic needs. Establishing biomarkers that have the potential to guide accurate CNS cancer diagnosis or are helpful in predicting disease progression or therapy response is of great interest. Cerebrospinal fluid (CSF) has been extensively targeted for the detection of molecules that might be useful markers for cancer detection. Central nervous system (CNS) cancer is a devastating illness with unmet therapeutic needs. Establishing biomarkers that have the potential to guide accurate CNS cancer diagnosis or are helpful in predicting disease progression or therapy response is of great interest. Cerebrospinal fluid (CSF) has been extensively targeted for the detection of molecules that might be useful markers for cancer detection. However, so far very few of such markers have found a standardized routine clinical application. This review examines the current scientific knowledge about the biochemical elements in the CSF that have been reported in the literature as brain cancer biomarkers and highlight reasons why the role of most markers is not yet established in the managment of CNS tumors.

show abstract

Cerebrospinal Fluid (Vascular Endothelial Growth Factor) and Serologic (Recoverin) Tumor Markers for Malignant Glioma

Abstract: Background: Clinically useful tumor markers have yet to be identified for malignant glioma. We report on two potential novel tumor markers, vascular endothelial growth factor (VEGF) and recoverin (protein A)

Cited by 59 publications

References 25 publications

Quantification of cerebrospinal fluid ferritin as a biomarker for CNS malignant infiltration

Quantification of cerebrospinal fluid ferritin as a biomarker for CNS malignant infiltration

Angiogenic potential of the cerebrospinal fluid (CSF) of patients with high-grade gliomas measured with the chick embryo chorioallantoic membrane assay (CAM)

Targeting cerebrospinal fluid for discovery of brain cancer biomarkers

Contact Info

Product

Resources

About